But disappointing that he has seen NO scripts for V. Shouldn’t need Evaporate data to have V prescribed. R-I like data for CVD has not been seen for over 30 years.
And V has been incorporated into medical society guidelines over a year ago. What have the reps been doing in his area?
jasbg, There will never be optimal usage of Vascepa unless or until AMRN is acquired by BP. If THAT never happens, then Vascepa, as a promising Cardiovascular drug approved in the US, will be "LAID TO WASTE!"